Acadia Pharmaceuticals drops on trial miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Wall Street ends down as oil prices, Treasury yields rise
TD Cowen Reiterates Buy Rating on Acadia Pharmaceuticals (ACAD)
September 24, 2026 12:20 PM EDTTD Cowen analyst Ritu Baral reiterated a Buy rating and $37.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
The analyst comments "Remlifanserin Ph2 ADP data just missed stat sig on the 1o EP of SAPS H+D (p=0.06) but nominal sig on key 2o EP... More
